首页> 美国卫生研究院文献>Hereditary Cancer in Clinical Practice >Comparison of whole genome amplification and nested-PCR methods for preimplantation genetic diagnosis for BRCA1 gene mutation on unfertilized oocytes–a pilot study
【2h】

Comparison of whole genome amplification and nested-PCR methods for preimplantation genetic diagnosis for BRCA1 gene mutation on unfertilized oocytes–a pilot study

机译:全基因组扩增和巢式PCR方法对未受精卵母细胞BRCA1基因突变的植入前遗传学诊断的比较–一项先导研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPreimplantation genetic diagnosis (PGD) remains nowadays a valid alternative for couples at high-risk of having a child with a genetic disease and for women older than 37–40 years with the high risk of chromosomal aneuploidies in the embryos. However the use of PGD for high penetrance recessive, dominant and X-liked disorders occurring in early life is documented, debate exists regarding its appropriateness in lower penetrance and late-onset cancer susceptibility syndromes. The data regarding the efficacy of different molecular techniques used in PGD are still lacking. We therefore sought to assess the different molecular techniques used in PGD for detecting three most frequent BRCA1 gene mutations: 5382insC, 185delAG and C61G.
机译:背景如今,对于有遗传病孩子的高风险夫妇和37-40岁且胚胎中染色体非整倍性风险较高的女性来说,植入前遗传学诊断(PGD)仍然是一种有效的选择。然而,已有文献报道PGD可用于早期生活中的高渗透性隐性,显性和X样疾病,关于其在低渗透性和晚期癌症易感性综合征中的适用性存在争议。仍然缺乏有关PGD中使用的不同分子技术的功效的数据。因此,我们寻求评估PGD中用于检测三种最常见的BRCA1基因突变的不同分子技术:5382insC,185delAG和C61G。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号